Table 1 Clinicopathological analysis of BTF3 expression in prostate cancer
From: BTF3 sustains cancer stem-like phenotype of prostate cancer via stabilization of BMI1
Variables | BTF3 expression | Total | P Value | |
|---|---|---|---|---|
Negative and weak | Moderate and strong | |||
Age (years) | Â | Â | Â | 0.279 |
  < 65 | 16 (53.3) | 14 (46.7) | 30 |  |
  > =65 | 114 (63.7) | 65 (36.3) | 179 |  |
Pre PSA (ng/ml) | Â | Â | Â | 0.727 |
  < 4 | 9 (56.3) | 7 (43.7) | 16 |  |
 4–10 | 15 (68.2) | 7 (31.8) | 22 |  |
  > =10 | 94 (65.3) | 50 (34.7) | 144 |  |
Gleason Score | Â | Â | Â | 0.006 |
  < 7 | 31 (83.8) | 6 (16.2) | 37 |  |
 7 | 75 (72.8) | 28 (27.2) | 103 |  |
  > 7 | 96 (59.6) | 65 (40.4) | 161 |  |
Stage | Â | Â | Â | 0.02 |
 T1-T2 | 98 (65.8) | 51 (34.2) | 149 |  |
 T3-T4 | 22 (46.8) | 25 (53.2) | 47 |  |
Metastasis | Â | Â | Â | 0.005 |
 Negative | 94 (67.1) | 46 (32.9) | 140 |  |
 Positive | 24 (45.3) | 29 (54.7) | 53 |  |
Ki67 | Â | Â | Â | 0.062 |
  < 10% | 128 (65.6) | 67 (34.4) | 195 |  |
  > 10% | 10 (45.5) | 12 (54.5) | 22 |  |
Biochemical recurrence | Â | Â | Â | 0.251 |
 Negative | 17 (65.4) | 9 (34.6) | 26 |  |
 Positive | 42 (52.5) | 38 (47.5) | 80 |  |
Clinical recurrence |  |  |  | < 0.001 |
 Negative | 84 (72.4) | 32 (27.6) | 116 |  |
 Positive | 33 (46.5) | 38 (53.5) | 71 |  |
CD44 | Â | Â | Â | 0.042 |
 Negative | 32 (91.4) | 3 (8.6) | 35 |  |
 Positive | 18 (69.2) | 8 (30.8) | 26 |  |
SOX2 | Â | Â | Â | 0.037 |
 Negative | 39 (79.6) | 10 (20.4) | 49 |  |
 Positive | 6 (50) | 6 (50) | 12 |  |